Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes

British Journal of Psychiatry

Volumn 192, Issue 2, 2008, Pages 135-143

  Tohen, Mauricio ^a,b   Bowden, Charles L ^c   Smulevich, Anatoly B ^d   Bergstrom, Richard ^a   Quinlan, Tonya ^a   Osuntokun, Olawale ^a   Wang, Wei V ^a   Oliff, Heather S ^e   Martenyi, Ferenc ^a   Kryzhanovskaya, Ludmila A ^a   Greil, Waldemar ^f  

^a ELI LILLY AND COMPANY   (United States)

^b MCLEAN HOSPITAL   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

^e Science Consulting Group   (United States)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; OLANZAPINE;

ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; LABORATORY TEST; MALE; MANIA; MONOTHERAPY; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VERTEBROBASILAR INSUFFICIENCY; VIRUS INFECTION; VITAL SIGN; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CARBAMAZEPINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 39449106319     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.107.041301     Document Type: Article

References (32)

1. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702-9.
2. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania. A double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57: 841-9.
3. Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH on behalf of the SPD417 Study Group. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005; 66: 323-30.
4. Weisler RH, Kalali AH, Ketter TA on behalf of the SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 478-84.
5. Zarate CA, Tohen M. Carbamazapine. In Comprehensive Textbook of Psychiatry (eds BJ Sadock, VA Sadock): 2282-8. Lippincott, Williams and Wilkins, 1999.
6. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149-73.
7. Licht RW, Vestergaard P, Kessing LV, Larsen JK, Thomsen PH on behalf of the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand Suppl 2003; 419: 1-22.
8. Vestergaard P. Guidelines for maintenance treatment of bipolar disorder: are there discrepancies between European and North American recommendations? Bipolar Disord 2004; 6: 519-22.
9. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 1998; 54: 639-43.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 2000.
11. First MBB, Spitzer RL, Williams JB. Structured Clinical Interview for DSM-IV AXIS I Disorders (Clinical Version) SCID-I Administration Booklet. American Psychiatric Publishing, 1997.
12. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-35.
13. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
14. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-71.
15. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
16. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education and Welfare, 1976.
18. National Cholesterol Education Program Expert Panel. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart, Lung, and Blood Institute, National Institutes of Health, 2002. NIH Publication number: 02-5215.
19. American Diabetes Association. Position statements and American Diabetes Association statements. Diabetes Care 2006; 29 (suppl 1): S75-7.
20. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003; 25: 46-53.
21. Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002; 24: 518-26.
22. Tegretol package insert. http://www.pharma.us.novartis.com/product/pi/ pdf/tegretol.pdf. Novartis Pharmaceutical Corporation, 2003.
23. Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry 2004; 65: 1679-87.
24. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263-71.
25. Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Ketter TA, Keck PE, Swann A, Kalali A on behalf of the SPD417 Study Group. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 2006; 20: 219-31.
26. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005; 162: 1879-87.
27. Ketter TA, Kalali AH, Weisler RH on behalf of the SPD417 Study Group. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 668-73.
28. Zyprexa package insert. http://pi.lilly.com/us/zyprexa-pi.pdf. Eli Lilly Corporation, 2006.
29. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481-9.
30. Yatham LN, Vieta E, Young AH, Möller HJ, Paulsson B, Vågerö M. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol 2007; 22: 212-20.
31. Vieta E, Carné X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom 2005; 74: 10-16.
32. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141-7.